Old Web
How Broad Are the Benefits of SGLT-2 Inhibitors?
2018
Clinical trials have shown that sodium-glucose cotransporter (SGLT-2) inhibitors significantly reduce adverse cardiovascular events, including death,
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI